Paraganglioma Clinical Trials 2023

What are the top hospitals conducting paraganglioma research?

In the realm of paraganglioma clinical trials, several top hospitals are making significant strides in research and treatment. One notable institution is the National Institutes of Health Clinical Center located in Bethesda. With three ongoing paraganglioma trials and a total of six conducted thus far, this center has been at the forefront of exploring new approaches since their initial trial in 2012. Another leading facility is Houston's renowned M D Anderson Cancer Center, which also boasts three active trials focused on paraganglioma alongside a cumulative tally of seven completed studies. Their groundbreaking efforts date back to 2010 when they first embarked on a paraganglioma trial.

The University of Iowa situated in Iowa City is another esteemed hospital that has dedicated its resources to addressing this condition. Currently conducting two active paraganglioma trials with a history including three previous investigations since their inaugural study in 2009, they continue to contribute valuable insights into this rare tumor type. Similarly, MD Anderson Cancer Center demonstrates its commitment by offering two ongoing paraganglioma trials and having accomplished three previous ones dating back to 2009.

Lastly, we turn our attention to Columbia University Medical Center located in New york City—an institution known for cutting-edge medical advancements. Despite being newer players within the field with just two active and two historical paraganglioma trials under their belt since recording their first investigation last year (in 2019), they have made notable progress towards improving outcomes for individuals affected by this unique form of tumor.

These hospitals represent beacons of hope for those battling against paragangliomas—rare tumors that can arise from specialized nerve cells found throughout the body—and highlight the importance placed upon research and innovation across various corners of America's healthcare landscape. As these institutions collaborate on pioneering clinical trials, patients can look forward to promising breakthroughs that may revolutionize treatment options while ultimately holding potential for many more lives to be saved in the future.

Which are the best cities for paraganglioma clinical trials?

When it comes to paraganglioma clinical trials, several cities have emerged as key players in research and advancements. New york, with its 8 active trials, focuses on studying treatments like Lanreotide, Axitinib, and Belzutifan. Anchorage in Alaska also offers 8 active trials that investigate Nivolumab and other potential therapies. Houston, Texas follows closely behind with 7 ongoing studies exploring Lutetium [177Lu] oxodotreotide/dotatate, EO2401, Belzutifan among others. Los Angeles in California also contributes significantly with 7 active trials examining Nivolumab and Doxazosin alongside other treatment options. Finally, Philadelphia in Pennsylvania conducts 4 active trials investigating Cohort B, Lutetium [177Lu] oxodotreotide/dotatate among other potential breakthroughs. These cities provide individuals diagnosed with paraganglioma access to cutting-edge clinical trials that offer hope for improved care outcomes through innovative treatments.

Which are the top treatments for paraganglioma being explored in clinical trials?

Exploring new frontiers in paraganglioma treatment, clinical trials have identified several promising approaches. One standout contender is talazoparib, currently undergoing one active trial dedicated to paraganglioma. Also making waves is lutetium [177Lu] oxodotreotide/dotatate, with one ongoing trial exclusively focused on this rare condition. Another exciting prospect is EO2401, which has demonstrated potential and sparked interest with its first listing in 2020 and involvement in a single active trial for paraganglioma. These breakthrough treatments offer hope for patients battling this challenging disease and pave the way for future advancements in care.

What are the most recent clinical trials for paraganglioma?

Exciting advancements are being made in the field of paraganglioma research, with recent clinical trials offering promising possibilities for treatment. One such trial explores dose escalation strategies to optimize efficacy and minimize side effects. Another focuses on the use of Lutetium [177Lu] oxodotreotide/dotatate as a potential therapeutic option. Talazoparib, an investigational drug, is also undergoing Phase 2 trials to evaluate its effectiveness against paraganglioma. Additionally, Belzutifan and Temozolomide have shown encouraging results in their respective studies. With these innovative approaches under investigation, there is hope for more effective treatments for patients battling paraganglioma in the near future.

What paraganglioma clinical trials were recently completed?

Mayo Clinic recently completed a clinical trial in May 2017 for Lenvatinib, a potential treatment for paraganglioma. This trial marks an important step in the research and development of therapies to combat this rare type of tumor. The completion of the study demonstrates Mayo Clinic's commitment to advancing medical knowledge and improving outcomes for patients with paraganglioma.